$2125 | SAVE $375 | Single User
$3825 | SAVE $675 | Enterprise License

Ulcerative colitis-Pricing & Market Access and Landscape- 2019

Ulcerative colitis-Pricing & Market Access and Landscape- 2019
[Lowest Price Guaranteed: $2,125]

Published by First View Insight: 15 Nov 2019 | 238872 | In Stock
Related Topics: Pricing

Introduction

Firstview Insight's Ulcerative colitis-Pricing & Market Access and Landscape- 2019 provides country specific insights in order to estimate market potential for Ulcerative colitis based on the pricing and reimbursement scenario and perceived value drivers in different market archetypes. It gives a detailed picture of the disease landscape and unmet needs of different stakeholders existing in the current treatment paradigmThus it enables to identify and leverage on the commercial opportunities spanning across different lines of therapy. The report incorporates detailed analysis of the market development drivers as well as the preventing factors. The scope of the report covers an extensive estimation pertaining to the winning essentials and participant schemes through a presentation of the segmentation of market in the Pricing & Market Access landscape.

Ulcerative colitis (UL-sur-uh-tiv koe-LIE-tis) is an inflammatory bowel disease (IBD) that causes long-lasting inflammation and ulcers (sores) in your digestive tract. Ulcerative colitis affects the innermost lining of your large intestine (colon) and rectum. Symptoms usually develop over time, rather than suddenly.

Ulcerative colitis can be debilitating and can sometimes lead to life-threatening complications. While it has no known cure, treatment can greatly reduce signs and symptoms of the disease and even bring about long-term remission.

Scope of the Report:

Market Access strategy for different payer archetypes

Segmentation and mapping of payers to different archetypes based on their specific criteria of assessment i.e. cost-effectiveness, budget impact, clinical effectiveness. This would enable designing effective market strategy for reimbursement in these markets. It also covers the reimbursement decisions and benefit ratings of competitor drugs by different health technology assessment bodies in EU5,US and Japan.

Payer Policy changes and implications

Provides an overview of the changing payer preferences, concerns and evolving requirements. Informs about the payer policies impacting the prescription and uptake of particular product. Estimates the future payer environment and drivers of change.

Innovative pricing and funding mechanisms

With increasing pressure from payers and limitations in evidence development, many innovative payment mechanisms are being introduced such as outcome based reimbursement, annuity based funding etc. This section provides examples of such innovative models and feasibility of their application in a particular disease scenario.

Disease Overview

This report contains comprehensive overview of disease including disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends, as well as details about treatment algorithms and treatment guidelines

Epidemiology

This section encompasses information on the incidence and prevalence of disease in EU5, US & Japan.

Existing and upcoming treatment landscape

Captures the evolution of treatment paradigm including the current and emerging drug therapies. Provides information on the clinical trial results, mechanism of action, route of administration, therapeutic positioning and regulatory milestones. It gives insight into the potential therapeutic targets for drug development.

Market Trends & Unmet needs

This section of the report helps to understand the market trend and opportunities by analysing the impact of current therapies on the market, current and future unmet needs, drivers and barriers and demand of better technology. This is determined by analysing the impact of various factors such as mechanism of action, route, cost of therapy, patient segmentation, existing available treatments, compliance and need of the market, expected launch timelines, competitors, brand value and KOLs perception.

Major highlights of the report

Detailed analysis of existing and upcoming competitive landscape

HTA decisions and benefit ratings for :

NICE (UK)

GBA (Germany)

HAS(ASMR and SMR)(France)

AIFA (Italy)

AEMPS (Spain)

SMC (Scotland)

ICER (US)

Chuikyo (Japan)

Market archetyping and product positioning

Case studies on innovative funding models

Unmet need, major barriers and drivers across the industry:

Value story for achieving reimbursement and premium pricing in different markets

Table of Contents
for Ulcerative colitis-Pricing & Market Access and Landscape- 2019

  • 1. Disease overview

    1.1. Pathophysiology

    1.2. Symptoms

    1.3. Etiology

    1.4. Diagnosis

    1.5. Treatment Algorithm

    1.6. Treatment Options

    2. Overview of Marketed drugs

    2.1 Dipentum

    2.1.1. Drug description

    2.1.2. Mechanism of action

    2.1.3 Clinical trials and regulatory milestones

    2.1.4 Pricing and market access landscape

    2.1.5 Pricing and market access drivers

    2.1.6 Adverse events

    2.2 Entyvio

    2.2.1. Drug description

    2.2.2. Mechanism of action

    2.2.3 Clinical trials and regulatory milestones

    2.2.4 Pricing and market access landscape

    2.2.5 Pricing and market access drivers

    2.2.6 Adverse events

    2.3 Humira

    2.3.1. Drug description

    2.3.2. Mechanism of action

    2.3.3 Clinical trials and regulatory milestones

    2.3.4 Pricing and market access landscape

    2.3.5 Pricing and market access drivers

    2.3.6 Adverse events

    2.4 Remicade

    2.4.1. Drug description

    2.4.2. Mechanism of action

    2.4.3 Clinical trials and regulatory milestones

    2.4.4 Pricing and market access landscape

    2.4.5 Pricing and market access drivers

    2.4.6 Adverse events

    2.5 Simponi

    2.5.1. Drug description

    2.5.2. Mechanism of action

    2.5.3 Clinical trials and regulatory milestones

    2.5.4 Pricing and market access landscape

    2.5.5 Pricing and market access drivers

    2.5.6 Adverse events

    2.6 Simponi

    2.6.1. Drug description

    2.6.2. Mechanism of action

    2.6.3 Clinical trials and regulatory milestones

    2.6.4 Pricing and market access landscape

    2.6.5 Pricing and market access drivers

    2.6.6 Adverse events

    2.7 Stelara

    2.7.1. Drug description

    2.7.2. Mechanism of action

    2.7.3 Clinical trials and regulatory milestones

    2.7.4 Pricing and market access landscape

    2.7.5 Pricing and market access drivers

    2.7.6 Adverse events

    3. Overview of Major Pipeline Drugs

    4. Summary of Pricing & Market Access landscape in USA, EU5, Australia and Canada

    5. Pricing of drugs in major markets

    6. Market Access strategy for different payer archetypes

    7. Drivers and Barriers

    8. Unmet Needs

    9. Innovative pricing and funding mechanisms

    10. Appendix

    11. Report Methodology

    12. Consulting Services

    13. Disclaimer

List Of Tables
in Ulcerative colitis-Pricing & Market Access and Landscape- 2019

Table 1: List of Marketed Drugs for Ulcerative colitis

Table 2: Market access landscape of Dipentum

Table 3: Market access landscape of Entyvio

Table 4: Market access landscape of Humira

Table 5: Market access landscape of Remicade

Table 6: Market access landscape of Simponi

Table 7: Market access landscape of Stelara

Table 8: Market access landscape of Xeljanz

Table 9: Major pipeline drugs

Table 10: Drivers and access barries

List Of Figures, Charts and Diagrams
in Ulcerative colitis-Pricing & Market Access and Landscape- 2019

Figure 1: Prices of therapies indicated for Ulcerative colitis in France

Figure 2: Prices of therapies indicated for Ulcerative colitis in UK

Figure 3: Prices of therapies indicated for Ulcerative colitis in Italy

Figure 4: Prices of therapies indicated for Ulcerative colitis in Germany

Figure 5: Prices of therapies indicated for Ulcerative colitis in Italy

Figure 6: Prices of therapies indicated for Ulcerative colitis in Spain

Figure 7: Prices of therapies indicated for Ulcerative colitis in USA

Figure 8: Prices of therapies indicated for Ulcerative colitis in Canada

Figure 9: Prices of therapies indicated for Ulcerative colitis in Australia

Additional Details

Publisher

First View Insight

Publisher Information

Our systems go beyond providing extensive comprehensive studies. We inspire our clients to develop knowledgeable growth mechanisms. Our insights are precise and approved by peer-driven research methodology. In brief, we pay emphasis on the success stories of our clients. When assessing solutions, we focus entirely on enabling them to influence their true potential for growth.



About FirstView Insight



FirstView Insight is a global market research and business consulting firm which focuses exclusively on healthcare domain. We help pharmaceutical companies to turn out to be progressively focused in a rapidly evolving market characterized by unpredictable product pipelines and uncertain regulatory actions.

Reference

238872 |

Number of Pages

180

Report Format

PDF

First View Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Ulcerative Colitis - Pipeline Review, H1 2017
Ulcerative Colitis - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical an...
09 May 2017 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2017
The Global Ulcerative Colitis Partnering Terms and Agreements since 2010 report provides understandi...
01 Apr 2017 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2017
The Global Ulcerative Colitis Partnering Terms and Agreements since 2010 report provides understandi...
01 Feb 2017 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Ulcerative Colitis Global Clinical Trials Review, H2, 2016
Ulcerative Colitis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report,...
28 Sep 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
Are UC biosimilars a real or perceived threat to branded drugs?Ulcerative colitis (UC) treatment is ...
01 Sep 2016 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Ulcerative Colitis: Update Bulletin [Feb 2016]
IntroductionGain new KOL insights on the latest events happening in Ulcerative Colitis. Topics cover...
01 Feb 2016 by FirstWord Pharma USD $846 (normally
USD $995)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
Introductionipeline drugs are poised to reshape the way doctors treat ulcerative colitis (UC). But w...
01 Dec 2015 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
IntroductionThe Ulcerative Colitis (UC) treatment market is already undergoing radical change as new...
03 Dec 2014 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info

This report is published by First View Insight

Our systems go beyond providing extensive comprehensive studies. We inspire our clients to develop knowledgeable growth mechanisms. Our insights are precise and approved by peer-driven research methodology. In brief, we pay emphasis on the success stories of our clients. When assessing solutions, we focus entirely on enabling them to influence their true potential for growth.

About FirstView Insight

FirstView Insight is a global market research and business consulting firm which focuses exclusively on healthcare domain. We help pharmaceutical companies to turn out to be progressively focused in a rapidly evolving market characterized by unpredictable product pipelines and uncertain regulatory actions.

Download Free Report Summary PDF

Ulcerative colitis-Pricing & Market Access and Landscape- 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...